722 related articles for article (PubMed ID: 15217805)
1. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice.
Suda O; Tsutsui M; Morishita T; Tanimoto A; Horiuchi M; Tasaki H; Huang PL; Sasaguri Y; Yanagihara N; Nakashima Y
Circulation; 2002 Sep; 106(13):1729-35. PubMed ID: 12270870
[TBL] [Abstract][Full Text] [Related]
3. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis.
Takemoto M; Egashira K; Tomita H; Usui M; Okamoto H; Kitabatake A; Shimokawa H; Sueishi K; Takeshita A
Hypertension; 1997 Dec; 30(6):1621-7. PubMed ID: 9403592
[TBL] [Abstract][Full Text] [Related]
4. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2.
Hasegawa K; Wakino S; Tatematsu S; Yoshioka K; Homma K; Sugano N; Kimoto M; Hayashi K; Itoh H
Circ Res; 2007 Jul; 101(2):e2-10. PubMed ID: 17601800
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine reduces nitric oxide donor-mediated dilation of arterioles by activating the vascular renin-angiotensin system and reactive oxygen species.
Veresh Z; Debreczeni B; Hamar J; Kaminski PM; Wolin MS; Koller A
J Vasc Res; 2012; 49(4):363-72. PubMed ID: 22652896
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats.
Akishita M; Nagai K; Xi H; Yu W; Sudoh N; Watanabe T; Ohara-Imaizumi M; Nagamatsu S; Kozaki K; Horiuchi M; Toba K
Hypertension; 2005 Jun; 45(6):1188-93. PubMed ID: 15867141
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.
Ohnishi K; Murase M; Nakano D; Pelisch N; Hitomi H; Kobori H; Morimoto S; Mori H; Masaki T; Ohmori K; Kohno M; Ichihara A; Nishiyama A
J Pharmacol Sci; 2013; 122(2):103-8. PubMed ID: 23698111
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
[TBL] [Abstract][Full Text] [Related]
9. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.
Chen JW; Hsu NW; Wu TC; Lin SJ; Chang MS
Am J Cardiol; 2002 Nov; 90(9):974-82. PubMed ID: 12398965
[TBL] [Abstract][Full Text] [Related]
10. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.
Zaman AK; Fujii S; Goto D; Furumoto T; Mishima T; Nakai Y; Dong J; Imagawa S; Sobel BE; Kitabatake A
J Mol Cell Cardiol; 2004 Aug; 37(2):525-35. PubMed ID: 15276022
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
Mihout F; Shweke N; Bigé N; Jouanneau C; Dussaule JC; Ronco P; Chatziantoniou C; Boffa JJ
J Pathol; 2011 Jan; 223(1):37-45. PubMed ID: 20845411
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
[TBL] [Abstract][Full Text] [Related]
14. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.
Antoniades C; Shirodaria C; Leeson P; Antonopoulos A; Warrick N; Van-Assche T; Cunnington C; Tousoulis D; Pillai R; Ratnatunga C; Stefanadis C; Channon KM
Eur Heart J; 2009 May; 30(9):1142-50. PubMed ID: 19297385
[TBL] [Abstract][Full Text] [Related]
15. Endothelial nitric oxide synthase-independent effects of an ACE inhibitor on coronary flow response to bradykinin in aged mice.
Talukder MA; Fujiki T; Morikawa K; Motoishi M; Matsuo Y; Hatanaka M; Tsutsui M; Takeshita A; Shimokawa H
J Cardiovasc Pharmacol; 2004 Nov; 44(5):557-63. PubMed ID: 15505492
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.
Ito A; Egashira K; Narishige T; Muramatsu K; Takeshita A
Circ J; 2002 Sep; 66(9):811-5. PubMed ID: 12224817
[TBL] [Abstract][Full Text] [Related]
17. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells.
Qiu H; Orr FW; Jensen D; Wang HH; McIntosh AR; Hasinoff BB; Nance DM; Pylypas S; Qi K; Song C; Muschel RJ; Al-Mehdi AB
Am J Pathol; 2003 Feb; 162(2):403-12. PubMed ID: 12547699
[TBL] [Abstract][Full Text] [Related]
18. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Zhuo JL; Mendelsohn FA; Ohishi M
Hypertension; 2002 Feb; 39(2 Pt 2):634-8. PubMed ID: 11882622
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
Ishiyama Y; Gallagher PE; Averill DB; Tallant EA; Brosnihan KB; Ferrario CM
Hypertension; 2004 May; 43(5):970-6. PubMed ID: 15007027
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.
Stühlinger MC; Conci E; Haubner BJ; Stocker EM; Schwaighofer J; Cooke JP; Tsao PS; Pachinger O; Metzler B
Cardiovasc Res; 2007 Jul; 75(2):417-25. PubMed ID: 17559823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
